# Oncimmune Holdings Agreement signed with major cancer center

- Link: https://www.directorstalkinterviews.com/oncimmune-holdings-agreement-signed-with-major-cancer-center/4121011252
- Published: 2021-07-23T07:10:48+01:00
- Author: Giles

**Oncimmune Holdings plc** (LON:ONC), the leading global immunodiagnostics group,
today announces it has signed an autoantibody profiling contract with Dana-Farber
Cancer Institute (“Dana-Farber”) in Boston, Massachusetts. Dana-Farber, a clinical
affiliate and research institute of Harvard Medical School, is a world-leading cancer
research organisation and one of America’s top-rated cancer hospitals with more 
than 1,100 therapeutic and non therapeutic clinical trials in progress.

Under this agreement, Oncimmune will be utilising its proprietary biomarker discovery
engine, SeroTag^(TM), to identify autoantibodies that can be predictive of patient
response or associated with resistance to checkpoint inhibitors (“CPIs”) and chemotherapy
used in Dana-Farber led studies or therapy using atezolizumab, nivolumab, pembrolizumab,
durvalumab and cisplatin-based chemotherapy. In addition, SeroTag will be used for
identifying autoantibodies that can be predictive of immune-related adverse events(“
irAEs”) in response treatment. The project is scheduled to complete by the end of
2021.

SeroTag is a high-throughput, multiplex, discovery technology based on Oncimmune’s
in-house protein library, one of the largest in the world, with a unique, ever-growing
repository of disease data for indications such as autoimmune and infectious diseases
as well as cancer. The proprietary SeroTag immuno-oncology discovery array is based
on autoantibody profiling studies in autoimmune diseases and other cancer types,
and comprises known and proprietary antigens linked to a number of cancers, autoimmune
and infectious diseases.

> **Dr Adam M Hill, CEO of Oncimmune Holdings said:**_ “We are delighted to be partnering
> with such a prestigious organisation as Dana-Farber on the use of multiple CPI
> assets in this important oncology trial and leveraging the power of our autoantibody
> biomarker profiling technology._
> _“As autoantibodies continue to be recognised as a key biomarker class that aid
> in the understanding of interactions between cancer and the immune system, the
> ImmunoINSIGHTS platform is becoming increasingly instrumental in studies for a
> wide range of cancer indications and therapy classes.” _

Share on:
